4 terminated, 3 completed, 2 recruiting, 2 unknown. 12 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Terminated 4, Completed 3, Recruiting 2, Unknown 2, Withdrawn 1 |
| Phase 1 | 4 | Completed 3, Recruiting 1 |
Follow vactosertib: new trials by email Literature Review of vactosertib trials Research Report on vactosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma Vactosertib, Standard of Care Preoperative Therapy - Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma | Phase 2 | Recruiting | Melissa Lumish | 25 | 2024-09-30 | 2026-10-05 |
| Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma Vactosertib - Osteosarcoma | Phase 1 / Phase 2 | Recruiting | MedPacto, Inc. | 78 | 2023-05-01 | 2026-10-07 |
| Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor Pembrolizumab, Vactosertib - Acral Melanoma, Mucosal Melanoma | Phase 2 | Terminated | Yonsei University | 14 | 2023-02-09 | 2025-04-02 |
| As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers Vactosertib - Gastric Cancer | Phase 2 | Unknown | Samsung Medical Center | 43 | 2022-10-01 | 2022-06-15 |
| Vactosertib and Durvalumab in Gastric Cancer durvalumab and vactosertib - Stomach Neoplasm | Phase 2 | Unknown | Hark Kyun Kim | 55 | 2021-06-01 | 2022-11-30 |
| Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF) Vactosertib, Imatinib - Dermoid | Phase 2 | Withdrawn | MedPacto, Inc. | 2021-06-01 | 2024-12-09 | |
| Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects Vactosertib 300 mg BID and pembrolizumab 200 mg IV - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | MedPacto, Inc. | 11 | 2020-12-17 | 2024-12-09 |
| Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients Vactosertib - Myeloproliferative Neoplasm | Phase 2 | Terminated | Weill Medical College of Cornell University | 2 | 2019-11-22 | 2025-07-02 |
| Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases Hepatectomy, Pembrolizumab, Vactosertib - Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8 | Phase 2 | Terminated | Chloe Atreya, MD, PhD | 6 | 2019-07-22 | 2025-12-31 |
| A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor vactosertib/imatinib combination - Desmoid Tumor | Phase 1 / Phase 2 | Completed | Hyo Song Kim | 24 | 2019-04-15 | 2024-05-13 |
| Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer TEW-7197 - Metastatic Colorectal Cancer, Gastric Cancer | Phase 1 / Phase 2 | Completed | MedPacto, Inc. | 120 | 2018-12-20 | 2025-03-25 |
| TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer TEW-7197 - Metastatic Gastric Cancer | Phase 1 / Phase 2 | Completed | MedPacto, Inc. | 62 | 2018-08-15 | 2024-12-09 |
Stomach Neoplasms (4) · Colorectal Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Anemia (1) · Carcinoma, Non-Small-Cell Lung (1) · Dermoid Cyst (1) · Desmoid Tumors (1) · Myeloproliferative Disorders (1) · Osteosarcoma (1)
MedPacto, Inc. (5) · Chloe Atreya, MD, PhD (1) · Hark Kyun Kim (1) · Hyo Song Kim (1) · Melissa Lumish (1) · Samsung Medical Center (1) · Weill Medical College of Cornell University (1) · Yonsei University (1)
South Korea (8) · United States (4)
Minkyu Heo (2) · Sunjin Hwang, MD (2) · Chloe Atreya, MD, Ph.D. (1) · Joseph M Scandura, MD, PhD (1) · Melissa Lumish, MD (1) · Minkyu Jung (1) · SeungTae Kim, PhMD (1)